Page last updated: 2024-08-21

cyclopentane and Myelodysplastic Syndromes

cyclopentane has been researched along with Myelodysplastic Syndromes in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (66.67)	24.3611
2020's	2 (33.33)	2.80

Authors

Authors	Studies
Adès, L; Bell, J; Campelo, MD; Cerrano, M; Faller, DV; Fram, RJ; Friedlander, S; Graux, C; Liesveld, J; Lopez, PF; Radinoff, A; Sangerman, MA; Sekeres, MA; Selleslag, D; Tzvetkov, N; Watts, J; Zeidner, JF; Zhao, D	1
Bowen, S; Dai, Y; Faller, DV; Friedlander, S; Haikawa, K; Hua, Z; Kupperman, E; Kuroda, S; Nakai, K; Sedarati, F; Venkatakrishnan, K; Yamamoto, Y; Yuan, Y; Zhou, X	1
Altman, JK; Bixby, DL; Blakemore, SJ; DeAngelo, DJ; Dezube, BJ; Erba, HP; Faessel, H; Giles, FJ; Hua, Z; Maris, M; Medeiros, BC; Sedarati, F; Swords, RT	1
Berger, AJ; Chalasani, S; Chen, S; Dai, Y; Dumur, CI; Ferreira-Gonzalez, A; Grant, S; Kmieciak, M; Leng, Y; Li, L; Lin, H; Povirk, L; Rahmani, M; Rizzo, KA; Zhang, Y; Zhou, L	1
Altman, JK; Anwer, F; DeAngelo, DJ; Dezube, BJ; Erba, HP; Faessel, H; Giles, FJ; Hua, Z; Maris, M; Medeiros, BC; Sedarati, F; Stein, H; Swords, RT; Watts, J	1
Finn, LE; Foran, JM; Hess, AD; Karp, JE; Kaufmann, SH; Knorr, KL; Smith, BD	1

Trials

4 trial(s) available for cyclopentane and Myelodysplastic Syndromes

Article	Year
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia, 2021, Volume: 35, Issue:7 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Pyrimidines	2021
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial. Clinical and translational science, 2021, Volume: 14, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Azacitidine; Cyclopentanes; Drugs, Investigational; Global Burden of Disease; Humans; Incidence; International Cooperation; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Myelodysplastic Syndromes; Pharmacology, Clinical; Pyrimidines; Translational Research, Biomedical; Ubiquitin-Activating Enzymes; United States	2021
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. British journal of haematology, 2015, Volume: 169, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Cyclopentanes; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Multiple Organ Failure; Myelodysplastic Syndromes; Pyrimidines; Ubiquitin-Activating Enzymes	2015
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood cancer journal, 2017, 02-03, Volume: 7, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cyclopentanes; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; NEDD8 Protein; Pyrimidines; Young Adult	2017

Other Studies

2 other study(ies) available for cyclopentane and Myelodysplastic Syndromes

Article	Year
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood, 2016, 05-05, Volume: 127, Issue:18 Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Cell Cycle Proteins; Cells, Cultured; Checkpoint Kinase 1; Cyclopentanes; DNA Damage; DNA Repair; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasm Proteins; NF-kappa B; Nuclear Proteins; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints; Sulfonamides; U937 Cells; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays	2016
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo. Stem cells translational medicine, 2017, Volume: 6, Issue:3 Topics: Cell Count; Cell Death; Cell Survival; Cyclopentanes; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines	2017

Article

Year

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Blood, 2016, 05-05, Volume: 127, Issue:18

Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Cell Cycle Proteins; Cells, Cultured; Checkpoint Kinase 1; Cyclopentanes; DNA Damage; DNA Repair; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasm Proteins; NF-kappa B; Nuclear Proteins; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints; Sulfonamides; U937 Cells; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays

2016

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.

Stem cells translational medicine, 2017, Volume: 6, Issue:3

Topics: Cell Count; Cell Death; Cell Survival; Cyclopentanes; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines

2017